Furthermore, in an in vivo model of pancreatic cancer, IFNγ treatment was shown to inhibit CXCL8 expression on tumor cells, reducing trafficking of suppressive CXCR2+CD68+ macrophages to the TME, restoring immune activity and response to anti-PD-1 therapy [167]. The gene discussed is CXCR2; the disease is neoplasm.